Marguerite Mensonides, COO and co-founder of Amplio Pharma. Photo: Sandra Doerpinghaus.
Amplio Pharma uses the latest scientific findings and modern technologies to considerably amplify the effect of some of today’s medications. In its first project, a new formulation of an existing drug is being developed that is expected to provide benefit to more than twice as many patients with rheumatoid arthritis, compared with currently available drugs. The company has been admitted to the SmiLe incubator program.
Rheumatoid arthritis is a chronic autoimmune disease that damages the joints, with severe pain and limited quality of life as a result. It is one of our common diseases and mainly affects women. Currently available medications do not cure the disease, but slow disease progression and reduce the symptoms for those who respond well to treatment.
Today’s rheumatoid arthritis drugs were developed about 70 years ago, with no significant improvement since that time. Only 30% of patients respond to treatment. Amplio Pharma intends to develop a new formulation that will dramatically increase that figure, so that 70% of patients will experience good effect from the drug.
“We’ve found a niche where we use our knowledge to ‘boost’ the efficacy of existing drugs. With our experience from drug development in global companies and knowledge of the latest research findings, we identify new approaches to amplify the effect of the active substance. In SmiLe’s incubator program, we receive expert help to develop the company as well as access to SmiLe’s well-equipped laboratories and network. It’s extremely exciting!” says Marguerite Mensonides, COO and co-founder of the company.
The company starts with tried and tested active ingredients. By using this approach, Marguerite Mensonides expects to be able to develop better medications than those currently available in less time and at a lower cost than is typical for drug development.
“This company focuses on modernizing old drugs, based on the solid background in drug development of its founders. Its economic and time-saving approach has great potential. The company’s focus on a common disease that affects women in particular is important for society in terms of both health economics and patient suffering. We are extremely pleased to be able to help them to design profitable business models and to develop the company,” says Ebba Fåhraeus.
Amplio Pharma is a spin-off from Truly Translational, which previously participated in SmiLe’s incubator program, and the US-based MPT Consultancy. The company has been granted a patent in Europe.
For more information, please contact: Marguerite Mensonides, COO and co-founder of Amplio Pharma, +46 (0)76 86 44 605, firstname.lastname@example.org
or Lina Boreson, COO SmiLe Incubator, +46 (0)703-78127,